Last updated: February 23, 2026
What is the drug associated with NDC 52268-0201?
NDC 52268-0201 corresponds to Rimegepant, marketed as Nurtec ODT. It is an oral calcitonin gene-related peptide (CGRP) receptor antagonist used for acute treatment and preventive management of migraine.
Market Overview
Indications and Competition
Nurtec ODT operates primarily within the migraine treatment market, which has seen significant growth due to expanding diagnosis rates and new therapeutic options. Market segments include:
- Acute migraine treatment: Caters to patients needing on-demand relief.
- Preventive migraine therapy: Targets frequent migraine sufferers.
Market Size
The global migraine drug market was valued at approximately USD 4.4 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 4.8% through 2028 [1].
In the U.S., the population of migraine sufferers exceeds 37 million, with about 30% seeking preventive treatment [2].
Competitive Landscape
Key competitors include:
- Erenumab (Aimovig) – CGRP monoclonal antibody.
- Fremanezumab (Ajovy) – CGRP monoclonal antibody.
- Galcanezumab (Emgality) – CGRP monoclonal antibody.
- Ditans and triptans – Past-standard acute therapies.
Nurtec ODT holds a niche with its oral formulation and dual indication, but faces pricing and reimbursement constraints from insurers.
Pricing Analysis
Current Pricing
- List Price (U.S.): Approximately USD 750 per 30-dose box [3].
- Average Wholesale Price (AWP): Similar figures, with actual negotiated prices usually lower.
Reimbursement Dynamics
Insurance coverage is evolving. Many plans require prior authorization; copay assistance programs are common, impacting net patient costs.
Patents and Market Exclusivity
Nurtec ODT obtained FDA approval in 2019. Patent protections extend until at least 2030, delaying generic entry.
Price Projections (Next 5 Years)
| Year |
Estimated Wholesale Price |
Assumptions & Drivers |
| 2023 |
USD 750 |
Existing list price, stable market penetration, no new competitors yet |
| 2024 |
USD 730 |
Slight price compression due to payer negotiations |
| 2025 |
USD 700 |
Increased payer pressure; introduction of biosimilar competitors (if patent challenged) |
| 2026 |
USD 680 |
Market saturation; expanded use in preventive therapy |
| 2027 |
USD 650 |
Increased generic competition; insurance discounts |
Note: These projections assume no significant regulatory changes, patent litigation failures, or rapid entry of generics, which could substantially lower prices.
Potential Market Drivers and Risks
Drivers:
- Growing migraine prevalence worldwide.
- Preference for oral medications.
- Expanded use for preventive therapy.
Risks:
- Patent expiration leading to generics.
- High drug costs leading to limited insurance coverage.
- Competition from emerging CGRP oral agents and new mechanism drugs.
Conclusion
Nurtec ODT (NDC 52268-0201) occupies a growing niche in migraine therapy, with a positioned price point reflecting premium status. Market expansion will depend heavily on reimbursement policies and competitive pressure from biosimilars and generics post-2030.
Key Takeaways
- The U.S. retail price remains around USD 750 per month.
- Market growth driven by increased prevalence and oral administration convenience.
- Price decline forecasted to approximately USD 650 by 2027, contingent on patent challenges and market entries.
- Competition from monoclonal antibodies remains significant but targeted for patients seeking oral options.
- Reimbursement strategies and formularies will influence actual patient costs and market penetration.
FAQs
1. When do generics for Nurtec ODT become available?
Patent expiration extends to at least 2030; generic entry is expected after patent challenges or expiration.
2. How does Nurtec ODT compare price-wise to monoclonal CGRP antibodies?
It is generally priced higher than monthly injectable biologics, which cost approximately USD 6,000–USD 8,000 annually. However, its oral route may justify premium pricing for certain patients.
3. What factors could disrupt current price projections?
Patent litigation outcomes, regulatory changes, or disruptive competition could lower prices earlier than projected.
4. How does insurance coverage impact market dynamics?
High out-of-pocket costs and stringent prior authorization processes may limit patient access, affecting sales growth.
5. Are there ongoing clinical trials promising future indications?
Current approvals focus on acute and preventive migraine; no highly promising alternative indications are currently in late-stage trials for Nurtec ODT.
References
[1] Grand View Research. (2022). Migraine Drugs Market Size, Share & Trends.
[2] American Migraine Foundation. (2021). Migraine Prevalence and Treatment Statistics.
[3] GoodRx. (2023). Nurtec ODT Pricing and Discounts.
This analysis synthesizes current market data and price trends to guide strategic decision-making for stakeholders involved with NDC 52268-0201.
